Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
42
ANIP Quote, Financials, Valuation and Earnings
Last price:
$82.67
Seasonality move
:
6.29%
Day range:
$81.59 - $83.47
52-week range:
$52.50 - $99.50
Dividend yield:
0%
P/E ratio:
50.70x
P/S ratio:
2.02x
P/B ratio:
3.67x
Volume:
390.9K
Avg. volume:
459.4K
1-year change:
45.52%
Market cap:
$1.9B
Revenue:
$614.4M
EPS (TTM):
$1.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 22% | 68.6% | $109.88 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$87M | -$0.09 | 53.91% | -88.43% | $31.63 |
|
BEAM
Beam Therapeutics, Inc.
|
$12.7M | -$1.01 | -54.98% | -2.35% | $45.93 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
HALO
Halozyme Therapeutics, Inc.
|
$339.1M | $1.61 | 33.63% | 78.39% | $76.00 |
|
NTLA
Intellia Therapeutics, Inc.
|
$14.1M | -$0.98 | -5.94% | -24.06% | $24.85 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
$82.67 | $109.88 | $1.9B | 50.70x | $0.00 | 0% | 2.02x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$29.96 | $31.63 | $3.7B | -- | $0.00 | 0% | 12.03x |
|
BEAM
Beam Therapeutics, Inc.
|
$26.74 | $45.93 | $2.7B | -- | $0.00 | 0% | 45.05x |
|
CRMD
CorMedix, Inc.
|
$10.32 | $19.00 | $813.1M | 5.03x | $0.00 | 0% | 3.47x |
|
HALO
Halozyme Therapeutics, Inc.
|
$64.66 | $76.00 | $7.6B | 13.59x | $0.00 | 0% | 6.53x |
|
NTLA
Intellia Therapeutics, Inc.
|
$9.06 | $24.85 | $1B | -- | $0.00 | 0% | 16.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.694 | 5.02% | 3.07x |
|
BEAM
Beam Therapeutics, Inc.
|
13.55% | 2.089 | 6.16% | 5.89x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
HALO
Halozyme Therapeutics, Inc.
|
74.99% | -0.702 | 17.53% | 1.26x |
|
NTLA
Intellia Therapeutics, Inc.
|
11.58% | 3.323 | 4.9% | 5.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
BEAM
Beam Therapeutics, Inc.
|
$4.1M | -$126.8M | -38.05% | -44.48% | -1307.6% | -$86.5M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
HALO
Halozyme Therapeutics, Inc.
|
$281.3M | $217.9M | 30.69% | 139.43% | 61.51% | $175.6M |
|
NTLA
Intellia Therapeutics, Inc.
|
$8.8M | -$111.5M | -47.33% | -54.66% | -808.86% | -$76.9M |
ANI Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ANIP or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of 7.47%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About ANIP or ARQT?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.88, signalling upside risk potential of 32.91%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 5.56%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is ANIP or ARQT More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.
-
Which is a Better Dividend Stock ANIP or ARQT?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or ARQT?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.70x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.02x versus 12.03x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.02x 50.70x $227.8M $24.1M ARQTArcutis Biotherapeutics, Inc.12.03x -- $99.2M $7.4M
-
Which has Higher Returns ANIP or BEAM?
Beam Therapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of -1162.38%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Beam Therapeutics, Inc.'s return on equity of -44.48%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B -
What do Analysts Say About ANIP or BEAM?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.88, signalling upside risk potential of 32.91%. On the other hand Beam Therapeutics, Inc. has an analysts' consensus of $45.93 which suggests that it could grow by 71.76%. Given that Beam Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 BEAMBeam Therapeutics, Inc.13 2 0 -
Is ANIP or BEAM More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison Beam Therapeutics, Inc. has a beta of 2.213, suggesting its more volatile than the S&P 500 by 121.346%.
-
Which is a Better Dividend Stock ANIP or BEAM?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beam Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Beam Therapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or BEAM?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Beam Therapeutics, Inc. quarterly revenues of $9.7M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Beam Therapeutics, Inc.'s net income of -$112.7M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.70x while Beam Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.02x versus 45.05x for Beam Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.02x 50.70x $227.8M $24.1M BEAMBeam Therapeutics, Inc.45.05x -- $9.7M -$112.7M
-
Which has Higher Returns ANIP or CRMD?
CorMedix, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of 49.9%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ANIP or CRMD?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.88, signalling upside risk potential of 32.91%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 84.11%. Given that CorMedix, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 CRMDCorMedix, Inc.4 0 0 -
Is ANIP or CRMD More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock ANIP or CRMD?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or CRMD?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.70x while CorMedix, Inc.'s PE ratio is 5.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.02x versus 3.47x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.02x 50.70x $227.8M $24.1M CRMDCorMedix, Inc.3.47x 5.03x $104.3M $108.6M
-
Which has Higher Returns ANIP or HALO?
Halozyme Therapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of 49.46%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Halozyme Therapeutics, Inc.'s return on equity of 139.43%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B HALOHalozyme Therapeutics, Inc.79.39% $1.43 $2B -
What do Analysts Say About ANIP or HALO?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.88, signalling upside risk potential of 32.91%. On the other hand Halozyme Therapeutics, Inc. has an analysts' consensus of $76.00 which suggests that it could grow by 17.54%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Halozyme Therapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Halozyme Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 HALOHalozyme Therapeutics, Inc.4 3 0 -
Is ANIP or HALO More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison Halozyme Therapeutics, Inc. has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.224%.
-
Which is a Better Dividend Stock ANIP or HALO?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Halozyme Therapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or HALO?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are smaller than Halozyme Therapeutics, Inc. quarterly revenues of $354.3M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is lower than Halozyme Therapeutics, Inc.'s net income of $175.2M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.70x while Halozyme Therapeutics, Inc.'s PE ratio is 13.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.02x versus 6.53x for Halozyme Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.02x 50.70x $227.8M $24.1M HALOHalozyme Therapeutics, Inc.6.53x 13.59x $354.3M $175.2M
-
Which has Higher Returns ANIP or NTLA?
Intellia Therapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of -735.19%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B NTLAIntellia Therapeutics, Inc.64.19% -$0.92 $846.4M -
What do Analysts Say About ANIP or NTLA?
ANI Pharmaceuticals, Inc. has a consensus price target of $109.88, signalling upside risk potential of 32.91%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 147.59%. Given that Intellia Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 NTLAIntellia Therapeutics, Inc.10 11 1 -
Is ANIP or NTLA More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.639% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.
-
Which is a Better Dividend Stock ANIP or NTLA?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or NTLA?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 50.70x while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 2.02x versus 16.51x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.2.02x 50.70x $227.8M $24.1M NTLAIntellia Therapeutics, Inc.16.51x -- $13.8M -$101.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
